5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

NCT07404332 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Locally Advanced Solid Tumor
Metastatic Tumor

Interventions

DRUG: 5 Azacytidine
DRUG: Pembrolizumab
DRUG: Nivolumab
DRUG: Cemiplimab

Sponsor

Mohammed Milhem